Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone

Prostate

Volumn 74, Issue 14, 2014, Pages 1462-1464

  Leibowitz Amit, Raya ^a   Alimohamed, Nimira ^a   Vera Badillo, Francisco E ^a   Seah, Jo An ^a   Templeton, Arnoud J ^a   Knox, Jennifer J ^a   Tannock, Ian F ^a   Sridhar, Srikala S ^a   Joshua, Anthony M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

abiraterone; mCRPC; re challenge

Indexed keywords

ABIRATERONE; DOCETAXEL; ENZALUTAMIDE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; HUMAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETREATMENT; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY;

ABIRATERONE; MCRPC; RE-CHALLENGE;

AGED; AGED, 80 AND OVER; ANDROSTADIENES; ENZYME INHIBITORS; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; STEROID 17-ALPHA-HYDROXYLASE;

EID: 84906351270     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22861     Document Type: Article

References (3)

1. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI,. Abiraterone and increased survival in metastatic prostate cancer. The New England journal of medicine 2011; 364 (21): 1995-2005.
2. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE,. Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England journal of medicine 2013; 368 (2): 138-148.
3. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M,. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2008; 26 (7): 1148-1159.